Browsing by Author "83f15db3-4c9e-4a3a-ae42-9de240287078"

Now showing items 1-6 of 6

    • A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the ... 
      Burmester, Gerd R.; McInnes, Iain B.; Kremer, Joel; Miranda, Pedro; Korkosz, Mariusz; Vencovsky, Jiri; Rubbert-Roth, Andrea; Mysler, Eduardo; Sleeman, Matthew A.; Godwood, Alex; Sinibaldi, Dominic; Guo, Xiang; White, Wendy I.; Wang, Bing; Wu, Chi Yuan; Ryan, Patricia C. (BMJ Publishing Group, 2017)
      Objectives: Despite the therapeutic value of current rheumatoid arthritis (RA) treatments, agents with alternative modes of action are required. Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage ...
    • A randomized phase IIb study of mavrilimumab and golimumab in Rheumatoid Arthritis 
      Weinblatt, Michael E.; McInnes, Iain B.; Kremer, Joel M.; Miranda, Pedro; Vencovsky, Jiri; Guo, Xiang; White, Wendy I.; Ryan, Patricia C.; Godwood, Alex; Albulescu, Marius; Close, David; Burmester, Gerd R. (Wiley, 2018)
      ObjectiveThis 24-week, phase IIb, double-blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte-macrophage colony-stimulating factor receptor ) and golimumab ...
    • Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison ... 
      Yoo, Dae Hyun; Prodanovic, Nenad; Jaworski, Janusz; Miranda, Pedro; Ramiterre, Edgar; Lanzon, Allan; Baranauskaite, Asta; Wiland, Piotr; Abud-Mendoza, Carlos; Oparanov, Boycho; Smiyan, Svitlana; Kim, Houng; Lee, Sang Joon; Kim, Suyeon; Park, Won (BMJ Publishing Group, 2017)
      © 2017 Published by the BMJ Publishing Group Limited.Objectives To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing ...
    • Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 ... 
      Park, Won; Yoo, Dae Hyun; Miranda, Pedro; Brzosko, Marek; Wiland, Piotr; Gutierrez-Ureña, Sergio; Mikazane, Helena; Lee, Yeon Ah; Smiyan, Svitlana; Lim, Mie Jin; Kadinov, Vladimir; Abud-Mendoza, Carlos; Kim, Houng; Lee, Sang Joon; Bae, Yunju; Kim, Suyeon; Braun, Jürgen (BMJ Publishing Group, 2017)
      Objectives To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS). Methods This open-label ...
    • Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin ... 
      Pavelka, Karel; Burgos-Vargas, Ruben; Miranda, Pedro; Guzman, Renato; Yen, Jeng Hsien; Izzi, Mustafa Al; Szekanecz, Zoltan; Tang, Boxiong; Szumski, Annette; Kotak, Sameer; Bananis, Eustratios; Koenig, Andrew S.; Mahgoub, Ehab Y.; Rahman, Mahboob U. (Future Medicine Ltd., 2014)
      © 2014 Future Medicine Ltd.Aims: We compared etanercept 50 mg once weekly (ETN50)/methotrexate versus etanercept 25 mg (ETN25)/methotrexate or biologic-free methotrexate after response to ETN50/methotrexate in moderate ...
    • Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid ... 
      Radominski, Sebastiao; Cardiel, Mario; Citera, Gustavo; Goecke Sariego, Irmgadt; Jaller, Juan José; Vannucci Lomonte, Andrea Barranjard; Miranda, Pedro; Vélez, Patricia; Xibille, Daniel; Kwok, Kenneth; Rojo, Ricardo; García, Erika Gabriela (Elsevier, 2017)
      Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety in the Latin American (LA) subpopulation of global Phase 3 and long-term ...